ReviewJournal of pain research2019
Pharmacological rationale for tapentadol therapy: a review of new evidence.
Review in Journal of pain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Efficacy of oral tapentadol immediate-release for the management of moderate-to-severe cancer pain in patients presenting to the oncology ward of a tertiary care hospital.Pakistan journal of medical sciences · 2026Article
- Reflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. 'Known Knowns, Known Unknowns, Unknown Unknowns'.Current oncology reports · 2025Review
- Review
- Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Variation in adverse drug events of opioids in the United States.Frontiers in pharmacology · 2023Article
- Prescribing trend of tapentadol in a Sydney local health district.British journal of clinical pharmacology · 2022Article
- A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors.Anesthesiology and pain medicine · 2022Review
- Perioperative Pain Management and Opioid Stewardship: A Practical Guide.Healthcare (Basel, Switzerland) · 2021Review
- Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights Into the Clinical Challenges of Pain Treatment?Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality.Drugs in context · 2021Article
- Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.Frontiers in chemistry · 2020Article
- Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children.Journal of pain research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain could be considered as a neurological disorder. Therefore, appropriate selection of the therapy, which should consider the pathophysiological mechanisms of pain, can result in a successful analgesic outcome. Tapentadol is an analgesic drug which acts both as a μ-opioid receptor (MOR) agonist and as a noradrenaline reuptake inhibitor (NRI), thereby generating a synergistic action in terms of analgesic efficacy, but not for the burden of adverse effects. Therefore, tapentadol can be defined as the first "MOR-NRI" drug. This molecule holds the potential to address at least some of the current limitations of analgesic therapy due to its unique mechanism of action and has shown to be safe and effective in the treatment of chronic pain of cancer and noncancer etiologies including nociceptive, neuropathic and mixed pain. In particular, the MOR component of tapentadol activity predominantly allows for analgesia in nociceptive pain; on the other hand, the NRI component contributes, now in a predominant manner, for analgesic efficacy in cases of neuropathic pain states. This paper will discuss recent pieces of evidence on the pathophysiology of pain, the background on tapentadol and then present some new studies on how the unique mechanism of action of tapentadol provides a key role in its analgesic efficacy in a number of pain states and with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.